Evidence map›Paper›PMID 34371540›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Effects of anti-liver fibrosis treatment on the occurrence of liver cancer in patients with hepatitis B-related liver cirrhosis].

K Shi, Q Zhang, Y Y Huang, X B Wang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. [Exploring the advantages of traditional Chinese medicine and dual-anti therapy for liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

K ShiDepartment of Integrated Chinese and Western Medicine, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing 100015, China The First Clinical School of Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
Q ZhangDepartment of Integrated Chinese and Western Medicine, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing 100015, China.
Y Y HuangDepartment of Integrated Chinese and Western Medicine, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing 100015, China The First Clinical School of Beijing University of Traditional Chinese Medicine, Beijing 100700, China.
X B WangDepartment of Integrated Chinese and Western Medicine, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing 100015, China.
Beijing Ditan Hospital · CNBeijing University of Chinese Medicine · CN

Funding

Capital Health Development Research Project 2018-1-2172National Natural Science Foundation of China 81774234Supported by Beijing Municipal Commission of Science and Technology Z191100006619033
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularHepatitis BHepatitis B, ChronicLiver NeoplasmsAntiviral AgentsHumansLiver CirrhosisRetrospective StudiesAntiviral AgentsAnti-fibrosis treatmentAntiviral therapyCirrhosisHepatitis BHepatocellular carcinoma

Identifiers

PMID34371540
PMCPMC12813988
OpenAlexW3187874445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.